|Articles|June 1, 2003

June 2003
Volume 9
Issue 6

High-Versus Low-dose Angiotensin Converting Enzyme Inhibitor Therapy in the Treatment of Heart Failure: An Economic Analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial

Author(s)J. Sanford Schwartz, MD, Y. Richard Wang, MD, PhD, John G. F. Cleland, MD

Download PDF: High-Versus Low-dose Angiotensin Converting Enzyme Inhibitor Therapy in the Treatment of Heart Failure: An Economic Analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial

Articles in this issue

over 22 years ago

Article

A Randomized Trial of an Acid-peptic Disease Management Program in a Managed Care Environment

over 22 years ago

Article

When Money Is Saved by Reducing Healthcare Costs, Where Do US Primary Care Physicians Think the Money Goes?

over 22 years ago

Article

Care Management Interventions for Older Patients with Congestive Heart Failure

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

A Health Economic Evaluation of Digital Digestive Care Management

ByMartha Shepherd, DO, MPH,Pen-Che Ho, MS,David Hines, BA,Jon Harris-Shapiro, BA,Dena Bravata, MD, MS,Christopher M. Whaley, PhD,K. Davina Frick, PhD,Emmanuel F. Drabo, PhD,Ron Z. Goetzel, PhD

January 21st 2026

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

ByShamsi Atefeh, PhD

January 15th 2026

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

ByMohamed M. Ali, MS,Scott Lunos, MS,Zachary Henderson, BSB,Michele Allen, MD, MS,Patricia Adam, MD, MSPH,Genevieve B. Melton, MD, PhD,Rubina Rizvi, MD, PhD

January 12th 2026

Subjective and Objective Impacts of Ambulatory AI Scribes

ByJulia Adler-Milstein, PhD,Orianna DeMasi, PhD,Hossein Soleimani, PhD,Sarah Beck, MDiv,Maria E. Byron, MD,Aris Oates, MD,Robert Thombley, BS,Jinoos Yazdany, MD, MPH,Sara G. Murray, MD, MAS

January 8th 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

High-Versus Low-dose Angiotensin Converting Enzyme Inhibitor Therapy in the Treatment of Heart Failure: An Economic Analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial

Articles in this issue

Newsletter

Related Content

Specialty and Operator Status Influence Electronic Health Record Use Variation

A Health Economic Evaluation of Digital Digestive Care Management

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

Subjective and Objective Impacts of Ambulatory AI Scribes

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

Health Insurance CEOs Questioned by House Committee About Rising Costs in Health Care

Semaglutide Shows Promise for Steatohepatitis Resolution in MASH

Advancing Biomarker Testing Across GU, Lung, and Myeloma Care

RWD Is Transforming Mental Health, Neurology Managed Care: Mitzi Wasik, PharmD

Socioeconomic Factors Linked to Surgical Outcomes in Upper Extremity Soft Tissue Sarcoma